Warrant buyback extinguishes warrant liability accounting and share dilution overhang RUTHERFORD, N.J., July 08, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it has successfully repurchased over 90% of its outstanding Series A Warrants…
Comprehensive analysis confirms safety and strong accuracy of Glucotrack’s innovative blood-based continuous glucose monitoring technology, with MARD of 7.7% RUTHERFORD, N.J. and STOCKHOLM, June 25, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced results from…
1-for-60 reverse stock split to become effective as of the opening of trading on June 16, 2025 Rutherford, NJ, June 12, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it…
Glucotrack to present on next-generation continuous blood glucose monitoring technology in Innovation Hub Poster presentation to highlight insights on safety and performance data from direct blood glucose measurement technology RUTHERFORD, N.J., June 04, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies…
Experienced medical device executive with deep expertise in implantable technologies joins Glucotrack as Company advances development of long-term implantable blood glucose monitoring technology RUTHERFORD, N.J., May 28, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, announced today…
Patients get a seat at the table in development of long-term implantable continuous blood glucose monitoring technology RUTHERFORD, N.J., May 20, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced the formation of a Patient Advisory…
On track to implant first patients in long-term, multicenter feasibility study of the fully implantable continuous blood glucose monitor (CBGM) system in Australia in Q3 2025 Investigational Device Exemption (IDE) approval for novel CBGM technology from FDA expected in Q4 2025 Rutherford, NJ, May 14, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or…
Long-term clinical evaluation represents key advancement following successful first-in-human study RUTHERFORD, N.J., May 13, 2025 (GLOBE NEWSWIRE) — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced it has received ethical approval from the St. Vincent’s…
Continuous Blood Glucose Monitor will be integrated with automated insulin delivery system for major EU diabetes study RUTHERFORD, N.J., April 16, 2025 — Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate…
Next Generation AI-Driven Analytics to Unlock Key Insights from the Ongoing Continuous Blood Glucose Monitoring Clinical Study Data RUTHERFORD, N.J. and STOCKHOLM, April 03, 2025 — Glucotrack, Inc. (Nasdaq: GCTK), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced an agreement with OneTwo Analytics…